DaVita Investor - Management (2024)

DaVita Investor - Management (1)

Javier J. Rodriguez

Chief Executive Officer, DaVita Inc.

Javier Rodriguez is the Chief Executive Officer of DaVita Inc., a global health care provider focused on improving the quality of life for patients through clinical innovation and integrated, personalized care. The company’s global operations include over 3,100 outpatient dialysis centers in 11 countries and 67,000 teammates serving more than 240,000 patients with kidney disease.

Mr. Rodriguez is an experienced leader committed to transforming care delivery for patients with kidney disease—from the earliest stages of the disease through transplantation. He is passionate about accelerating the digital transformation and delivering customized care to each patient while lowering costs for the health care system. In more than 20 years with DaVita, he has continued fostering a powerful sense of inclusivity and community among teammates and patients.

Since joining the company in 1998, Mr. Rodriguez has served in a number of capacities, including leading kidney care operations and payor contracting. Prior to joining DaVita, Mr. Rodriguez worked in finance for Baxter Healthcare Corporation and in operations for CBS Marketing Inc. in Mexico City.

Mr. Rodriguez has been widely recognized for his leadership by Fierce Healthcare, Modern Healthcare and Hispanic Executive, among others. He serves on the board of directors for Gilead Sciences Inc. (NASDAQ:GILD). Mr. Rodriguez is one of 550 CEOs of the world’s leading organizations to sign the CEO Action Pledge for Diversity & Inclusion.

Mr. Rodriguez earned a master’s degree from Harvard Business School and a bachelor’s degree in finance and marketing from Boston College.

DaVita Investor - Management (2)

Michael D. Staffieri

Chief Operating Officer, DaVita Kidney Care

Michael D. Staffieri became our Chief Operating Officer, DaVita Kidney Care, in March 2014. From July 2011 to February 2014, he served as a Senior Vice President, Kidney Care. Mr. Staffieri initially joined us in July 2000 and served in different roles since that time, including as our Vice President of Operations and New Center Development form March 2008 to July 2011. Prior to joining us, Mr. Staffieri worked for Arthur Andersen LLP in Finance from 1999 to 2000.

DaVita Investor - Management (3)

Robert Lang

President, DaVita International

Robert Lang became our President and Chief Executive Officer of International in April 2017 and has played an integral role in positioning the company for strong international growth of 19% per annum since 2017. DaVita's International business spans 11 countries and provides care for more than 40,000 kidney disease patients outside of the United States. Robert has led the expansion of DaVita International further into Asia and the UK and has overseen the expansion of our clinical services in Europe, South America and Saudi Arabia. Robert has brought a strong commitment to improving outcomes and patient experience in every clinic DaVita operates around the world. Robert is a serving Board member for Bridge of Life (BOL), an independent public charity and international nonprofit organization working to strengthen healthcare globally through sustainable programs that prevent and treat chronic disease. Prior to joining DaVita, Robert has held leadership positions at Bupa, UBS and HSBC. Robert served in the Australian Army from 1991-1998.

DaVita Investor - Management (4)

Joel Ackerman

Chief Financial Officer, DaVita Inc.

Joel Ackerman became our Chief Financial Officer in February 2017 after serving as our Senior Vice President, Finance from February 2017 to February 2017. Effective April 2019, Mr. Ackerman was also appointed to serve as our Treasurer. Prior to joining us, Mr. Ackerman was the chief executive officer and a member of the board of directors of Champions Oncology, Inc., a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, since October 2010. Mr. Ackerman is currently the chairman of the board of Champions Oncology. Mr. Ackerman served as a managing director at Warburg Pincus, a global private equity firm, where he led the healthcare services team for 10 years from January 1999 to September 2008. He served on the board of directors at Kindred Healthcare, Inc. a post-acute provider in the United States, from December 2008 to July 2018, and served on the board of directors of Coventry Health Care, Inc. a national managed care company, from September 1999 until its acquisition by Aetna Inc. in May 2013. He is also chairman of the board of One Acre Fund, a not-for-profit organization that focuses on smallholder agriculture, and serves subsistence farmers in Africa.

DaVita Investor - Management (5)

Christopher M. Berry

Chief Accounting Officer, DaVita Inc.

Christopher M. Berry became our Chief Accounting Officer in September 2023. Mr. Berry brings more than 25 years of accounting and finance experience to DaVita. Prior to joining us as Group Vice President, Accounting in August 2023, Mr. Berry was the senior vice president and chief accounting officer at Sonder Holdings Inc. (“Sonder”), a publicly traded hospitality company, from August 2022 to August 2023. He also previously served as Sonder’s interim principal financial officer from January 2023 to March 2023. Prior to joining Sonder, Mr. Berry held various roles at Alaska Air Group, Inc., a publicly traded airline holding company, serving as vice president, corporate controller, and chief accounting officer from February 2017 to April 2022, managing director of accounting, corporate controller and principal accounting officer from February 2014 to February 2017, managing director, investor relations from October 2010 to February 2014, and director, financial reporting and accounting from March 2005 to October 2010. Mr. Berry holds a Bachelor of Business Administration from the University of Louisiana Monroe and a CPA license in the State of Washington.

DaVita Investor - Management (6)

Jeffrey A. Giullian

Chief Medical Officer, DaVita Kidney Care

Jeffrey Giullian, MD, serves as chief medical officer of DaVita Kidney Care. Dr. Giullian leads the transformation of kidney care through his commitment to providing holistic, integrated care that addresses the clinical and psychosocial needs of patients. Dr. Giullian is focused on pushing the boundaries on exemplary clinical care through innovation and expanding what is possible for patients living with kidney disease.

Since joining DaVita in 2016, Dr. Giullian previously served as chief medical officer of hospital services, vice president of medical affairs and national group medical director at DaVita Kidney Care. Dr. Giullian relies on his past experiences in private practice and hospital leadership to advocate for patients, physicians and medical directors. He is active with the Renal Physicians Association (RPA) as a member of the Board of Directors, chairman of the Healthcare Payment Committee and member of the RPA’s team of advisors to the American Medical Association Relative Value Units Utilization Committee. Dr. Giullian trained in nephrology and transplantation at Vanderbilt University and received his MBA from the University of Colorado at Denver.

DaVita Investor - Management (7)

Kathleen A. Waters

Chief Legal & Public Affairs Officer

Kathleen A. Waters became our Chief Legal Officer in May 2016, overseeing all legal and regulatory functions for the enterprise. In February 2021, Ms. Waters became our Chief Legal and Public Affairs Officer as she also took over responsibility for government affairs. Prior to joining us, Ms. Waters was senior vice president, general counsel and secretary of Health Net, Inc., a publicly traded managed care organization, from April 2015 to March 2016. Prior to Health Net, Inc., she was a partner in Morgan, Lewis & Bockius LLP's litigation practice from 2003 to 2015, where she was co-chair of the healthcare group. Before that, Ms. Waters was a partner at Brobeck, Phleger & Harrison LLP in Los Angeles.

DaVita Investor - Management (8)

James O. Hearty

Chief Compliance Officer, DaVita Inc.

James O. Hearty became our Chief Compliance Officer in March 2018. From September 2015 to March 2018, he served as our Senior Vice President and Chief Compliance Officer, DaVita Kidney Care, and, prior to that, from February 2012 to August 2015, he served as Vice President, Associate General Counsel. Prior to joining us, he was a prosecutor and trial attorney with the U.S. Department of Justice (DOJ) for 14 years. He started in the Civil Division of the DOJ in Washington D.C. and four years later became an Assistant U.S. Attorney in the U.S. Attorney’s Office for the District of Colorado. Mr. Hearty held several leadership positions at the U.S. Attorney’s Office, including deputy chief of the criminal division. Mr. Hearty also serves on the board of Urban Peak, a Denver non-profit that serves homeless youth.

DaVita Investor - Management (9)

Tina Livaudais

Chief Nursing Officer, DaVita Inc.

Tina Livaudais is the chief nursing officer for DaVita Kidney Care, where she focuses on clinical experience and patient safety. Tina is an established leader in the nursing field, with over 28 years in clinical leadership roles at every level of the organization.

She started her DaVita tenure in 1995 as a patient care technician (PCT) in New Orleans, Louisiana. Her passion for personalized, high-touch care deepened, and Tina went on to serve as a facility administrator, regional operations director, division vice president of Hospital Services and vice president of Clinical Services for a multi-state region before her latest role as chief nursing officer.

Tina is passionate about continuous education and development, often advocating through guest lectures and presentations to nursing groups across the U.S. In 2017, Tina was honored with the Chairman’s Award for her inspirational leadership style and strong advocacy for nurses and PCTs, and in 2023, Tina was named one of Fierce Healthcare’s Women of Influence.

DaVita Investor - Management (2024)

FAQs

Is DaVita stock a good investment? ›

DaVita has 2.60% upside potential, based on the analysts' average price target. DaVita has a consensus rating of Hold which is based on 0 buy ratings, 3 hold ratings and 1 sell ratings. The average price target for DaVita is $143.50.

Is DaVita doing well financially? ›

Consolidated revenues were $3.071 billion. Operating income was $484 million and adjusted operating income was $463 million. Diluted earnings per share was $2.65 and adjusted diluted earnings per share was $2.38. Operating cash flow was $(135) million and free cash flow was $(327) million.

Who owns the most DaVita stock? ›

Largest shareholders include Berkshire Hathaway Inc, Vanguard Group Inc, BlackRock Inc., State Street Corp, Pacer Advisors, Inc., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Invesco Ltd., VFINX - Vanguard 500 Index Fund Investor Shares, Geode Capital Management, Llc, and NAESX - Vanguard Small-Cap ...

Is DaVita investment grade credit? ›

DaVita holds an investment grade rating of BB from Standard & Poor's, and a long term rating of Ba2 from Moody's.

Does Warren Buffett own DaVita stock? ›

Warren Buffett's Acquisition of DaVita Shares

The significance of this investment within Berkshire's equity portfolio cannot be overstated. Owning 40.71% of the outstanding DaVita stock, Buffett's firm has a commanding influence over the company's direction and decision-making processes.

Is DaVita undervalued? ›

DVA has a P/S ratio of 0.99. This compares to its industry's average P/S of 1.32. These are only a few of the key metrics included in DaVita's strong Value grade, but they help show that the stock is likely undervalued right now.

Who is bigger Fresenius or DaVita? ›

Largest dialysis providers in the U.S. in 2019, by number of patients. In 2019, Fresenius Medical Center North America had over 208 thousand dialysis patients, the most of any dialysis provider in the United States. DaVita Kidney Care followed with 204 thousand patients on dialysis.

How much debt does DaVita have? ›

Total debt on the balance sheet as of March 2024 : $11.84 B

According to DaVita's latest financial reports the company's total debt is $11.84 B. A company's total debt is the sum of all current and non-current debts.

Did United healthcare buy DaVita? ›

UnitedHealth's Optum unit has completed its $4.3 billion acquisition of DaVita Medical Group after getting the final OK from the Federal Trade Commission (FTC).

Is DaVita Dialysis a Fortune 500 company? ›

The company is ranked 357th on the Fortune 500. The name "DaVita" was derived from the Italian language phrase "Dare Vita", which means "to give life".

What is the financial performance of DaVita? ›

Operating income was $1,603 million and adjusted operating income was $1,734 million for year ended December 31, 2023. Diluted earnings per share from continuing operations was $1.62 and adjusted diluted earnings per share from continuing operations was $1.87 for three months ended December 31, 2023.

What is a strong investment grade credit rating? ›

Higher rated companies are considered investment grade, suggesting strong underlying fundamentals and a good capacity to pay a bond's principal and interest. Issues that are investment grade are rated as "BBB" or "Baa" or higher by ratings agencies such as Standard & Poor's and Moody's.

What is the stock price forecast for DaVita in 2025? ›

On average, Wall Street analysts predict that Davita's share price could reach $144.33 by May 15, 2025. The average Davita stock price prediction forecasts a potential upside of 0.81% from the current DVA share price of $143.18.

What is the dividend of DaVita? ›

The current TTM dividend payout for DaVita (DVA) as of June 10, 2024 is $0.00. The current dividend yield for DaVita as of June 10, 2024 is 0.00%.

What is the target price for PCOR stock? ›

Based on analyst ratings, Procore Technologies's 12-month average price target is $81.73. What is PCOR's upside potential, based on the analysts' average price target? Procore Technologies has 23.93% upside potential, based on the analysts' average price target.

How profitable is DaVita? ›

DaVita Inc.

DVA delivered adjusted earnings per share (EPS) of $2.38 in the first quarter of 2024, up 50.6% year over year. The figure topped the Zacks Consensus Estimate by 21.4%. GAAP EPS for the quarter was $2.65, reflecting a surge of 112% year over year.

References

Top Articles
Latest Posts
Article information

Author: Duncan Muller

Last Updated:

Views: 5665

Rating: 4.9 / 5 (59 voted)

Reviews: 90% of readers found this page helpful

Author information

Name: Duncan Muller

Birthday: 1997-01-13

Address: Apt. 505 914 Phillip Crossroad, O'Konborough, NV 62411

Phone: +8555305800947

Job: Construction Agent

Hobby: Shopping, Table tennis, Snowboarding, Rafting, Motor sports, Homebrewing, Taxidermy

Introduction: My name is Duncan Muller, I am a enchanting, good, gentle, modern, tasty, nice, elegant person who loves writing and wants to share my knowledge and understanding with you.